Suscribirse

Mid-term follow up effectiveness of facemask treatment in class III malocclusion: A systematic review - 23/07/21

Doi : 10.1016/j.ortho.2021.07.003 
Lydia Kakali 1, Isidora Christopoulou 1, , Ioannis A. Tsolakis 1, Dimitris Sabaziotis 1, Antigoni Alexiou 1, Mattheos Sanoudos 1, Apostolos I. Tsolakis 1, 2
1 University of Athens, School of Dentistry, Department of Orthodontics, Athens, Greece 
2 Case Western Reserve University, School of Dental Medicine, Department of Orthodontics, Cleveland, OH, USA 

Isidora Christopoulou, University of Athens, School of Dentistry, Department of Orthodontics, Thivon Street, 15127 Athens, Greece.University of Athens, School of Dentistry, Department of OrthodonticsThivon StreetAthens15127Greece
En prensa. Pruebas corregidas por el autor. Disponible en línea desde el Friday 23 July 2021
This article has been published in an issue click here to access

Summary

Objective

This systematic review aims to investigate and summarize the mid-term effects and stability of the treatment with facemask appliance.

Methods

Search without restrictions in five databases (Pubmed, Medline, Embase, Scopus, Cochrane Central Register of Controlled Trials) since inception and hand searching until March 2021 was conducted. Detailed search strategies were based on the PubMed strategy and adapted accordingly. Studies assessing the mid-term effects of facemask appliance, with a follow-up post-treatment period of more than 6 years or after the peak of pubertal growth, were to be included. The risk of bias in individual studies was assessed using the Cochrane guidelines for the RCT and the ROBINS-I tool for the non-RCT studies.

Results

Five studies were finally considered eligible for inclusion (one RCT and four CCTs). According to the reported evidence, the mid-term success rate ranged from 62.7% to 100%. Mid-term success was identified with positive overjet as well as acceptable aesthetic and functional characteristics.

Conclusions

Class III malocclusion treated with facemask presents a high percentage of success in the mid-term follow-up period. The mid-term effects of facemask were stable for the maxilla, in terms of sagittal and anteroposterior dentoskeletal dimensions, and any kind of relapse is attributed to uncontainable residual growth of the mandible. However, considering the high risk of bias and the follow-up period limitations, more high-quality studies are necessary in order to achieve further clarification. Future research should be based also on identifying biomarkers to indicate likely treatment responses.

Registration number

PROSPERO: CRD42020179402.

El texto completo de este artículo está disponible en PDF.

Keywords : Orthodontic appliance, Facemask, Malocclusion angle class III, Extraoral traction appliance, Reverse headgear


Esquema


© 2021  CEO. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.